Biotech Is Heating Up — These 2 Red‑Hot Stocks Stand Out

Biotech stocks are once again capturing investor attention as innovation and regulatory progress drive excitement in the sector. MarketBeat highlights two biotechnology companies — Axsome Therapeutics (NASDAQ: AXSM) and Innoviva (NASDAQ: INVA) — as particularly noteworthy as we kick off 2026, each with catalysts that could fuel future growth. Axsome has seen significant momentum from two recent FDA regulatory updates: the acceptance of a supplemental filing for its investigational oral treatment AXS‑05 for agitation in Alzheimer’s patients, and FDA backing for an application for AXS‑12, targeting narcolepsy. These advancements support Axsome’s expanding pipeline and come alongside a strong revenue uptick — nearly 63% year‑over‑year — though the company still faces challenges with profitability. Analysts remain bullish, with most giving the stock Buy ratings and price targets above current levels. On the other hand, Innoviva’s spotlight comes from the FDA approval of Nuzolvence, a first‑in‑class oral antibiotic for treating gonorrhea — a condition affecting millions globally. This newly approved therapy replaces previous injectable options and addresses rising antibiotic resistance, positioning Innoviva for potential market impact. Prior to this, Innoviva had already shown strong financial performance with solid earnings and revenue growth. While biotech shares can be volatile due to clinical and regulatory risks, both Axsome and Innoviva offer compelling stories centered on recent FDA actions and product developments that may shape their growth trajectories in the coming quarters. #BiotechStocks #FDAApprovals #AxsomeTherapeutics #Innoviva #SlimScan #GrowthStocks #CANSLIM